**Becker 2015** Becker C, Boettcher M.-F. Study 17116: Interaction study to investigate the influence of a starting dose of 500 mg followed by multiple doses of 250 mg mefenamic acid every 6 hours on pharmacokinetics as well as safety and tolerability of a single dose of 2.5 mg vericiguat in comparison to a single dose of 2.5 mg vericiguat alone in healthy male subjects in a randomized, non-blinded, non-placebo-controlled, two-fold cross-over design. Bayer AG Clinical study report. 2015 Oct. Report-No. PH-38616.
***confidential data***

**Champion 1978** Champion GD, Graham GG: Pharmacokinetics of non-steroidal anti-inflammatory
agents. Aust NZ J Med. 8 (Supp 1): 94-100, Jun 1978.

**DrugBank DB00784** (https://www.drugbank.ca/drugs/DB00784)

**Fricke 2020** Fricke R. Vericiguat: Investigations on Binding of Atazanavir to Recombinant UGT1A1 and of Mefenamic Acid to Recombinant UGT1A9. 2020. Report-No. PH-41346.

**Goosen 2016** Goosen TC, Callegari E, Lin J, Tse S, Sahasrabudhe V. Physiologically based Pharmacokinetic Modeling of Drug-drug Interaction following Coadministration of Ertugliflozin and UGT Inhibitor Mefenamic Acid. Presented as poster at the 7th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigations of Drug-Drug Interactions. 2016 May 29-31. Marbach Castle, Germany.

**Goosen 2017** Goosen TC, Callegari E, Lin J, Tse S, Sahasrabudhe V. Characterization of UGT Inhibition as a
Necessary and Important Strategy in Drug Development. Presented at the 20th Anniversary of the International Conference on Drug-Drug Interactions , Washington. 2017 June 21. Seattle, Washington, USA. (https://www.ifscomm.org/wp-content/uploads/2015/04/2017-06-21-GOOSEN_UGT-DDI_FINAL.pdf)

**Hamaguchi 1987** Hamaguchi T, Shinkuma D, Yamanaka Y, Mizuno N. Effects of food on absorption of mefenamic acid from two commercial capsules differing in bioavailability under the fasting state. J Pharmacobiodyn. 1987 Jan;10(1):21-5.

**Jungmann 2019** Jungmann N. Vericiguat: Determination of Ki Values of Atazanavir on 3-Glucuronidation of 17Î²-Estradiol via UGT1A1 and of Mefenamic Acid on Glucuronidation of Propofol via UGT1A9. Bayer AG Nonclinical study report. 2019 Aug. Report-No. PH-41095.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**Mahadik 2013** Mahadik M, Dhaneshwar S, Bhavsar R. A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. Biomed Chromatogr. 2012 Oct;26(10):1137-42. doi: 10.1002/bmc.1755.

**Nishimura 2013** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003 May;123(5):369-75.	

**Ohtsuki 2012** Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, Terasaki T. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012 Jan;40(1):83-92. doi: 10.1124/dmd.111.042259.	

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)	

**Rouini 2004** Rouini MR, Asadipour A, Ardakani YH, Aghdasi F. Liquid chromatography method for determination of mefenamic acid in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Feb 5;800(1-2):189-92.

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589.

**Vitas-M Lab ID: STK666691** (https://www.vitasmlab.biz/finded-stk/?stk=STK666691)